Cadisc-L implants - Press release
PDF | 207.06 KB
To ensure the greatest possible transparency, the Hirslanden Private Hospital Group has decided to publish, in anonymised form, the independent research findings on the Cadisc-L implants used by the hospital group. The final report by the independent law firm Baumgartner Mächler can be accessed on the company’s website. For privacy protection reasons, the names of the affected patients and the doctors involved have been anonymised. Based on the research findings, the hospital group has also decided to introduce a public register of vested interests of the doctors employed at the hospital group.
This will ensure that patients will in future have full transparency on the vested interests of their attending physician with regard to the use of implants, substances or methods of treatment. In addition, the Hirslanden Private Hospital Group has further refined its existing system for monitoring the use of pharmaceutical products through additional supervision by an in-house expert panel. With these measures, the Hirslanden Group undertakes to further enhance its responsibility towards its patients with regard to quality and patient safety.
As of 31 March 2019, the Hirslanden Private Hospital Group comprises 18 hospitals in 11 cantons, many of which have an outpatient surgical centre and an Emergency department. The Group also operates 3 outpatient clinics, 2 outpatient surgery units, 17 radiology institutes and 5 radiotherapy institutes. The Group has 2,303 affiliated doctors and 10,442 employees, of whom 510 are permanently employed doctors.
Hirslanden is the leading private hospital group and the largest medical network in Switzerland. In the 2018/19 financial year, the Group generated turnover of CHF 1,778 million. As at 31 March 2019, the Group had treated 106,851 patients, amounting to a total of 479,631 inpatient days. In insurance terms, the patient mix consists of 48.7% basic, 29.5% semi-private, and 21.8% private insured patients.
The Hirslanden Private Hospital Group is synonymous with first-class medical care provided by highly qualified medical specialists with years of experience. As a system provider, Hirslanden stands out from the rest of the market: interdisciplinary medical centres of expertise and specialised institutes enable it to offer the best possible individualised treatment, even in highly complex cases. The Hirslanden Private Hospital Group was formed in 1990 through the merger of several Swiss private hospitals. Since 2007 it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.
For privacy protection reasons, the names of the affected patients and the doctors involved have been anonymised. The report is only available in German.